This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Baxter (BAX) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
Baxter's (BAX) first-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.
Baxter International (BAX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 22.92% and 1.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q1 Earnings on Apr 27: WST, DXCM, BAX
by Zacks Equity Research
Medical Device companies' Q1 results are likely to reflect strength in customer demand. Let's see how WST, DXCM and BAX are placed ahead of their earnings releases.
Are Investors Undervaluing Baxter International (BAX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Baxter (BAX) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
Baxter's (BAX) New Premix Drug Now Available in the U.S.
by Zacks Equity Research
Baxter's (BAX) latest frozen premix formulation is expected to support patient safety, simplify medication preparation and boost operational efficiencies.
Baxter (BAX) Q4 Earnings Miss Estimates, FY23 Outlook Weak
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results reflect impact of additional sales from the legacy Hilrom's business acquired in 2021. Ongoing macroeconomic challenges hurt earnings significantly.
Baxter International (BAX) Lags Q4 Earnings Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of -6.38% and 3.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Quipt Home Medical Corp. (QIPT) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Baxter International (BAX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency and supply challenges. Hillrom's products are likely to have boosted sales.
Company News for Jan 10, 2023
by Zacks Equity Research
Companies In The News Are: REGN, LULU, DCT, BAX.
Baxter (BAX) Plans to Form Standalone Kidney Care Company
by Zacks Equity Research
Baxter (BAX) plans several strategic actions, including spin-off of Renal Care and Acute Therapies global business units into an independent, publicly traded company to simplify its operating model.
Is the Options Market Predicting a Spike in Baxter International (BAX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Baxter International (BAX) stock based on the movements in the options market lately.
Baxter (BAX) Q3 Earnings Meet Estimates, Hilrom Adds $735 M
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
Baxter International (BAX) Q3 Earnings Match Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 0% and 0.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.
MacroGenics (MGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and bottom lines.
Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances.
Is a Beat Likely for DexCom (DXCM) This Earnings Season?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
Neogen (NEOG) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and 2.51%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?